MUSA-PRoMISe

Proteomics and Pathway Analysis of Women With Mixed Urinary Incontinence-MUSA Supplementary

The primary aim of the PRoMISe study is to characterize baseline putative proteins/protein pathways in women with MUI associated with change in UDI after treatment with MUS or onabotulinum toxin A (i.e., MUSA Trial original subjects, N=110).

Secondary aims include:

  1. Characterizing baseline putative proteins/protein pathways in women with MUI associated with change in the stress and urgency UI subscales of the UDI after treatment with MUS or onabotulinum toxin A (MUSA Trial subjects)
  2. Comparing up- and down-regulation of proteins associated with these 2 treatments (N=55/arm) for women with MUI 6 months post-treatment within and between groups.
  3. Looking at associations of diet via food frequency assessment and proteomics in women with MUI.